Medical News

RSS

LEADLESS II study confirms positive benefits of St. Jude Medical’s Nanostim leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim™ leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.

3 Sep 2015

World leaders meet at World Hepatitis Summit to discuss prevention strategies for viral hepatitis

Today marks the start of the first-ever World Hepatitis Summit hosted in Glasgow, Scotland, at the Scottish Exhibition and Conference Centre.

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

Nearly all advanced esophageal cancers harbor genetic mutations that can be targeted with emerging drug therapies, according to a new study published in The Oncologist on September 2, 2015.

3 Sep 2015

Automatic cell counting in 30 seconds with the Olympus Cell Counter R1

Olympus has unveiled the Cell Counter model R1, engineered with leading-edge technology that offers user-friendly and cost-effective cell counting for routine cell culturing in a portable design.

3 Sep 2015

Researchers develop new method that can target drug delivery to the lung

Researchers from Columbia Engineering and Columbia University Medical Center have developed a new method that can target delivery of very small volumes of drugs into the lung.

3 Sep 2015

Study reveals presence of new genetic mutation in melanoma cancer cells

There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has revealed that a genetic mutation leading to repression of a specific protein, Cdh1, which interacts with APC/C, is present in melanoma cancer cells.

3 Sep 2015

Acal BFi inks channel partner agreement in Europe with SynQor

Acal BFi, European leader in advanced technology solutions, have signed a channel partner agreement in Europe with SynQor to include UK, Ireland, Denmark, Sweden, Norway, Finland, Belgium, Netherlands, Luxemburg and Italy.

3 Sep 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Lannett enters into definitive agreement to purchase KU for $1.23 billion

Lannett Company, Inc. today announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments.

3 Sep 2015

NxThera obtains FDA clearance for Rezūm System to treat BPH

NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE) platform technology to treat endourological conditions, is pleased to announce it has received FDA 510(k) clearance of the company's Rezūm System to treat BPH.

3 Sep 2015

Boca Raton Regional Hospital introduces ultra-minimally invasive procedure for patients with atrial fibrillation

Boca Raton Regional Hospital's Richard G. Cartledge, MD, FACS, has begun performing ultra-minimally invasive left atrial appendage ligation for atrial fibrillation patients who are on anticoagulants such as Coumadin, Xarelto or Effient. Dr. Cartledge, who is Chief of Cardiothoracic Surgery at the Hospital, is one of a select group of surgeons nationally using this method, which involves making two microscopic incisions in order to seal off the left atrial appendage (LAA) in patients where anticoagulants are contraindicated or who refuse to be on such medications.

3 Sep 2015

Prime Healthcare Services acquires St. Joseph Mercy Port Huron

Prime Healthcare Services, the fastest growing hospital system in the nation, announced today that it has completed the acquisition of St. Joseph Mercy Port Huron. As a result, St. Joseph Mercy Port Huron will now be known as Lake Huron Medical Center.

3 Sep 2015

Preventing the build up of dangerous biofilms, ESCMID publishes guidelines

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that explores the risks and best practices in infectious disease – advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms, which contribute to antimicrobial resistance.

2 Sep 2015

Surgical training resource developed by medical students

Medical students from the University of Leicester’s Medical School have developed a free educational resource for medical students and junior doctors that teaches valuable surgical skills they will need during their training.

2 Sep 2015

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.

2 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

EarlySense releases myEarlySense for digital health consumer market

EarlySense, the market leader in contact-free, health and wellness sensing and analytics, announced today the release of myEarlySense, its first OEM solution for the digital health consumer market. The new sleep and wellness monitoring solution will be showcased at the upcoming IFA event, taking place in Berlin on September 4-9.

2 Sep 2015

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million.

2 Sep 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Medical News

LEADLESS II study confirms positive benefits of St. Jude Medical’s Nanostim leadless pacemaker

World leaders meet at World Hepatitis Summit to discuss prevention strategies for viral hepatitis

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

Automatic cell counting in 30 seconds with the Olympus Cell Counter R1

Researchers develop new method that can target drug delivery to the lung

Study reveals presence of new genetic mutation in melanoma cancer cells

Acal BFi inks channel partner agreement in Europe with SynQor

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Lannett enters into definitive agreement to purchase KU for $1.23 billion

NxThera obtains FDA clearance for Rezūm System to treat BPH

Boca Raton Regional Hospital introduces ultra-minimally invasive procedure for patients with atrial fibrillation

Prime Healthcare Services acquires St. Joseph Mercy Port Huron

Preventing the build up of dangerous biofilms, ESCMID publishes guidelines

Surgical training resource developed by medical students

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

EarlySense releases myEarlySense for digital health consumer market

Ascletis completes US$35 million (RMB 220 million) financing

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News